Butantrone

Butantrone

SCHEMBL2109872

CCCC(=O)C1c2cccc(O)c2C(=O)c2c(O)cccc21

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.43
MEN1 O00255 1/20 0.42
USP2 O75604 1/20 0.42
ALDH1A1 P00352 1/20 0.42
HPN P05981 1/20 0.42
CYP3A4 P08684 1/20 0.42
ALOX5 P09917 1/20 0.42
MAPT P10636 1/20 0.42
THRB P10828 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
PTGS1 P23219 1/20 0.42
PDE4A P27815 1/20 0.42
KDR P35968 1/20 0.42
KMT2A Q03164 1/20 0.42
HSD17B10 Q99714 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11292310 0.91 CES2 (0.47) CES2MEN1ALDH1A1MAPTKMT2A
SCHEMBL10631861 0.89 ALDH1A1 (0.44) CES2ALDH1A1MAPTALOX15TSHR
SCHEMBL8073087 0.81 KEAP1 (0.42) ALDH1A1MAPT
SCHEMBL10780202 0.80 SLC25A5 (0.50)
SCHEMBL8076275 0.80 CYP19A1 (0.46) MEN1USP2ALDH1A1HPNCYP3A4
SCHEMBL8076262 0.79 ACHE (0.46) TDP1
SCHEMBL8427797 0.78 HDAC4 (0.39)
SCHEMBL8427798 0.78 HDAC4 (0.39)
SCHEMBL10630399 0.78 ALDH1A1 (0.47) MEN1USP2ALDH1A1HPNCYP3A4
SCHEMBL8063137 0.77 ACHE (0.51) ALOX5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
CN-101330905-A Freeze-drying process and products obtained thereby SCIDOSE LLC (US) 2008-12-24 CN claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
EP-1336602-A1 Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases Scaramuzzino, Giovanni (IT) 2003-08-20 EP claimed
EP-0017420-B1 NEW DIHYDROXY-ACYLANTHRONES HAVING ANTI-PSORIATIC ACTIVITY, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE AS ANTI-PSORIATIC AGENTS ORION-YHTYMÄ OY (FI) 1982-07-21 EP claimed
EP-0017420-A1 New dihydroxy-acylanthrones having anti-psoriatic activity, process for preparing them, pharmaceutical compositions comprising them, and their use as anti-psoriatic agents ORION-YHTYMÄ OY (FI) 1980-10-15 EP claimed
US-20220047505-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2022-02-17 US disclosed
US-11191719-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2021-12-07 US disclosed
US-10463611-B2 Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration STI PHARMA, LLC (US) 2019-11-05 US disclosed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US disclosed
US-20140154313-A1 Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration STI PHARMA, LLC (US) 2014-06-05 US disclosed
WO-1995003266-A1 10-SUBSTITUTED 1,8-DIHYDROXY-9(10H) ANTHRACENONE PHARMACEUTICALS TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 1995-02-02 WO disclosed
WO-1994006748-A1 NEW ANTHRONE AND ANTHRACENE DERIVATIVES SUBSTITUTED IN POSITION 10, PROCESS FOR THEIR PRODUCTION, PHARMACEUTICALS OR COSMETICS CONTAINING SAID COMPOUNDS, AND THEIR USE BEIERSDORF AG (DE) 1994-03-31 WO disclosed
US-4696941-A SKIN DISORDERS, ANTIINFLAMMATORY AGENTS Groupement d'Interet Economique dit: Centre International 'de Recherches Dermatologiques C.I.R.D. (FR) 1987-09-29 US disclosed
EP-0017420-B1 NEW DIHYDROXY-ACYLANTHRONES HAVING ANTI-PSORIATIC ACTIVITY, PROCESS FOR PREPARING THEM, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM, AND THEIR USE AS ANTI-PSORIATIC AGENTS ORION-YHTYMÄ OY (FI) 1982-07-21 EP disclosed
US-4299846-A Dihydroxy-acylanthrones having anti-psoriatic activity ORION-YHTYMA OY (FI) 1981-11-10 US disclosed
EP-0017420-A1 New dihydroxy-acylanthrones having anti-psoriatic activity, process for preparing them, pharmaceutical compositions comprising them, and their use as anti-psoriatic agents ORION-YHTYMÄ OY (FI) 1980-10-15 EP disclosed